Loading…
← CockpitCompetitor Analysis › XERS Xeris Biopharma Holdings, Inc.Open in the cockpit ↗

Xeris Biopharma Holdings, Inc.XERSCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Makes ready-to-use injectable and delivery technologies for hormone deficiency and endocrine drugs.

Momentum leader 100
Mkt cap
$3.10B
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$47.4M
20-day average traded
Fwd P/E
49.7×
forward earnings
ROIC−WACC
+16.8 pp
WACC 8.9%
Hurdle
-41 pp
Req g minus delivered
Next earnings
112 days
10 Mar 2027
Close · USD$16.99
1D+1.1%
1W+2.9%
1M+52.6%
3M+97.6%
6M+172.7%
YTD+116.4%
1Y+134.0%
ATR %4.2%
Beta0.09
52w lowhigh1.7% off high

What Xeris Biopharma does

Makes ready-to-use injectable and delivery technologies for hormone deficiency and endocrine drugs.

Earns from selling three branded drugs in the US, mostly through wholesalers and pharmacies, with insurers deciding coverage. Gvoke serves diabetes, a large patient group, while Recorlev and Keveyis treat rare conditions with few prescribers. The 2021 merger with Strongbridge Biopharma brought in the two rare-disease drugs.

Products and services

  • Gvoke (ready-to-use glucagon, severe hypoglycemia)
  • Recorlev (Cushing's syndrome)
  • Keveyis (rare periodic paralysis)

Customers

  • Endocrinologists
  • Diabetes patients/caregivers

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Injectable drug delivery for endocrine…

What could go right

  • Gvoke market share growth vs nasal/injectable rivals
  • Recorlev commercial ramp

What could go wrong

  • Competitive glucagon/endocrine drug market
  • Small-cap financing and dilution risk

Moat: narrow (IP / patents, process know-how). Proprietary non-aqueous formulation technology avoids the reconstitution steps needed by rival products.

Headquarters: Chicago, Illinois, US · Founded: 2005 · Employees: 435

Named competitors

Xeris Biopharma at a glance

Size Xeris Biopharma (XERS) is a United States Health Care company (Biotechnology) with a market value of $3.10B, the 1515th largest of 3,085 United States companies the cockpit tracks. Shares closed at $16.99 on 18 Nov 2026.

Performance Over six months the shares gained 172.7%, against +2.8% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 38.4% over the last twelve months (peer median +6.3%); the operating margin is 12.7% (peer median -31.7%).

Valuation It trades at 49.7× forward earnings against a peer median of 26.7× (2nd most expensive of 8).

Price implies For today's price to make sense, revenue must grow about 29% a year for seven years (Req g). Recent delivered growth is +70%, so the hurdle is -41 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 16.8 points above its cost of capital (8.9% WACC).

Backlog Backlog (remaining performance obligations) was $6.20M at 30 Sep 2026 — 0.0 years of trailing revenue. Backlog detail →

Short interest Short interest is 4.9% of the free float (30 Oct 2026).

Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).

Relative performance

10020021 May 202621 Aug 202618 Nov 2026XERS 266Peer median 103
Six months, rebased to 100: Xeris Biopharma against the median of its 20 peers (local-currency closes).

Xeris Biopharma financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$368M$292M$203M$164M$110M
Revenue growth—+44%+24%+49%—
Gross profit$311M$238M$155M$124M$76.8M
EBITDA$59.6M$37.6M-$21.0M-$30.9M-$67.8M
Net income-$6.50M$554,000-$54.8M-$62.3M-$94.7M
Free cash flow$72.6M$27.9M-$37.8M-$50.5M-$103M
Capital expenditure$1.03M$696,000$868,000$2.26M$524,000
Total debt$226M$258M$271M$229M$198M

Quarterly statements and history in the cockpit →

Xeris Biopharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%+150%-25%0%+25%+50%VIRP002007ADMATLXDYNRUBICONELVN69192228BAVA9688IOVAIRON028300ABCLMBXRLAYXERS6-month return →1-month return →
Up and to the right = strong over both horizons. Xeris Biopharma is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%20×40×60×VIRP002007ADMATLXRUBICONBAVA600161XERSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Xeris Biopharma is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%25%50%75%VIRP002007ADMABAVA600161XERSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Xeris Biopharma is the large dot.

Xeris Biopharma competitors and peer comparison

Head to head with its named competitors (XERS vs LLY vs NOVO-B.CO)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Xeris Biopharma XERS$3.10B+173%+38%13%49.7×29.5%
Lilly (Eli) LLY$1.30T+36%+46%51%29.5×6.5%
Novo Nordisk A/S NOVO-B.CO$177B-6%+6%48%11.8×-0.5%

How Xeris Biopharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Xeris Biopharma against its 20 peers (data as of 18 Nov 2026)
MeasureXERSPeer medianRank in peer set
1-month return+52.6%-4.6%highest of 21
6-month return+172.7%+2.8%highest of 21
Distance from 52-week high-1.7%-27.8%highest of 21
Revenue growth (TTM)+38.4%+6.3%3rd highest of 16
Operating margin12.7%-31.7%7th highest of 17
Forward P/E49.7×26.7×2nd most expensive of 8
Growth the price implies (Req g, 7 yrs)29.5%2.2%most demanding of 6
Growth delivered (Del g)+70.2%+12.5%highest of 6
Hurdle (Req g minus delivered)-40.7 pp-10.3 pp2nd least demanding of 6
ROIC minus cost of capital+16.8 pp-9.4 pp2nd highest of 16
EV / EBITDA53.7×12.8×3rd most expensive of 6
Net debt / EBITDA1.6×0.5×3rd most indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Xeris Biopharma XERSUnited States$3.10B+173%+38%13%49.7×29.5%+70.2%
Virbac VIRP.PAFrance$3.20B-4%+4%15%16.6×5.8%+9.4%
Hualan Biological Engineering 002007.SZChina$3.20B-17%-11%17%26.7×15.8%-1.8%
ADMA Biologics ADMAUnited States$3.01B+58%+6%45%16.7×-0.8%+64.6%
Telix Pharmaceuticals TLX.AXAustralia$2.99B-2%+27%-1%34.5×n/an/a
Dyne Therapeutics DYNUnited States$2.97B-10%n/an/an/an/an/a
Denali Therapeutics DNLIUnited States$2.95B-2%n/a-2,488%n/an/an/a
Rubicon Research RUBICON.NSIndia$2.94B+68%+37%21%66.6×n/an/a
Enliven Therapeutics ELVNUnited States$3.30B+7%n/an/an/an/an/a
Caliway Biopharmaceuticals 6919.TWTaiwan$3.32B-25%-54%-6,983%n/an/an/a
XtalPi 2228.HKHong Kong$2.87B-34%+4%-127%n/an/an/a
Bavarian Nordic A/S BAVA.CODenmark$2.82B+23%-8%18%16.6×-4.3%+27.4%
Zai Lab 9688.HKHong Kong$2.79B+23%0%-63%n/an/an/a
Iovance Biotherapeutics IOVAUnited States$3.46B+111%+51%-61%n/an/an/a
Beijing Tiantan Biological Products 600161.SSChina$3.47B-13%-13%21%33.1×2.2%+12.5%
Sunshine Lake Pharma 6887.HKHong Kong$2.72B-7%+20%-3%n/an/an/a
Disc Medicine IRONUnited States$3.55B+16%n/an/an/an/an/a
HLB 028300.KSSouth Korea$2.69B-49%+26%-96%n/an/an/a
AbCellera Biologics ABCLUnited States$3.60B+141%+92%-298%n/an/an/a
MBX Biosciences MBXUnited States$2.65B+70%n/an/an/an/an/a
Relay Therapeutics RLAYUnited States$3.65B+27%+24%-3,095%n/an/an/a

Xeris Biopharma backlog

Xeris Biopharma reported $6.20M of remaining performance obligations at 30 Sep 2026 and up 24% from the previous quarter. That is 0.0 years of trailing revenue already under contract. Book-to-bill last quarter: 1.01.

Questions

Who are Xeris Biopharma's main competitors?
Named competitors: Eli Lilly (Baqsimi) (LLY), Novo Nordisk (NOVO-B.CO). The cockpit's measured peer set (industry) also includes Virbac (VIRP.PA), Hualan Biological Engineering (002007.SZ), ADMA Biologics (ADMA), Telix Pharmaceuticals (TLX.AX), Dyne Therapeutics (DYN), Denali Therapeutics (DNLI).
Is Xeris Biopharma expensive compared with its peers?
On forward p/e it trades at 49.7× against a peer median of 26.7×, 2nd most expensive of 8 in its peer set. For today's price to make sense, revenue must grow about 29% a year for seven years (Req g). Recent delivered growth is +70%, so the hurdle is -41 pp: the price already allows for a slowdown.
How has Xeris Biopharma stock performed?
Over six months to 18 Nov 2026 the shares returned +172.7% against +2.8% for the median peer; over one year +134.0%.
What is Xeris Biopharma's backlog?
Xeris Biopharma's remaining performance obligations (contracted revenue not yet recognised) were $6.20M at 30 Sep 2026.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.